Accessibility Menu
Orchestra BioMed logo

Orchestra BioMed(NASDAQ) OBIO

Market Cap$322.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-52%
5 Year-45%
1 Year+115%
1 Month+48%
Premium Feature
Moneyball Superscore
53/100
$5.37
-1.11%
-0.06Today
After hours$5.39+$0.02 (+0.37%)
Orchestra BioMed last closing stock price
MetricPriceDate
Last closeUSD 5.362026-08-21
Orchestra BioMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+21.54%USD 4.412026-08-14
1 month+47.66%USD 3.632026-07-22
3 month+32.02%USD 4.062026-05-22
Year to date+29.16%USD 4.152025-12-31
1 year+115.26%USD 2.492025-08-21
3 year-15.32%USD 6.332023-08-22
5 year-45.22%USD 9.792021-08-20
Since inception-52.37%USD 11.402020-08-04

Orchestra BioMed Financials at a Glance

Market Cap

$322.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.98M

Net Income (TTM)

-$59.03M

EPS (TTM)

-$1.00

P/E Ratio

-5.36

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$5.37

Volume

276,667

Open

$5.45

Previous Close

$5.36

Daily Range

$5.27 - $5.53

52-Week Range

$2.20 - $5.78

Estimated Earnings Date

Nov 9, 2026

OBIO News

hearthealth

Why Shares of Orchestra BioMed Jumped Tuesday

James HalleySep 19, 2023
Nurse tending patient in intensive care (1)

Why Shares of Orchestra BioMed Holdings Jumped Wednesday

James HalleyJun 28, 2023
nurse and doctors in masks discussing chart

Why Shares of Orchestra BioMed Jumped This Week

James HalleyMar 24, 2023

OBIO: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. makes heart and blood pressure tools. These devices help doctors treat patients with blocked heart arteries. The company partners with large makers to reach more hospitals.

High-Tech Heart Solutions

  • AVIM Therapy: Bioelectronic treatment for high blood pressure delivered through a dual-chamber pacemaker.
  • Virtue SAB: Angioplasty balloon system that delivers a liquid drug directly to blocked heart arteries.
  • FreeHold Retractors: Surgical tools used to hold tissue during minimally invasive procedures; sold in the United States.

The Road to Approval

  • Partnered with Medtronic to develop AVIM Therapy for patients who require cardiac pacemakers.
  • Secured a $35.0 million funding agreement with Ligand Pharmaceuticals in July 2025 based on future royalty rights.
  • Obtained a $20.0 million convertible loan from Medtronic in May 2026 to fund specific therapy integration work.
  • Terminated a distribution and development agreement with Terumo Corporation in Oct. 2025.
  • Entered the Russell 3000 and Russell 2000 indexes on June 26, 2026.

Sharing Risks and Rewards

The company uses a partnership model to share development risks and potential rewards with industry leaders. This strategy allows the firm to focus on clinical trials while utilizing established global distribution networks.

By the Numbers

  • Total revenue was $198,000 for the six months ended June 30, 2026, down 88% year over year.
  • Net loss was $44.4 million for the six months ended June 30, 2026, up 17% year over year.
  • Research and development expenses rose 18% to $32.4 million during the six months ended June 30, 2026.
  • The company held $110.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
  • Interest expense reached $2.6 million in the first half of 2026 compared to interest income in 2025.

Bottom Line

Orchestra BioMed has transitioned from a development-stage firm to a clinical-stage company with multiple candidates in pivotal trials. Its strategy relies on collaborations with industry giants to navigate the path toward regulatory approval.

AI Generated • Aug 11, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

86

CEO

David P. Hochman

Website

www.orchestrabiomed.com

Headquarters

New Hope, PA 18938, US

OBIO Financials

Key Financial Metrics (TTM)

Gross Margin

99.32%

Operating Margin

-181.36%

Net Income Margin

-184.60%

Return on Equity

-125.93%

Return on Capital

-65.30%

Return on Assets

-51.02%

Earnings Yield

-18.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$322.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.11M

Volume

276.67K

Avg. Volume

340.79K

Financials (TTM)

Gross Profit

$31.76M

Operating Income

-$57.99M

EBITDA

-$57.10M

Operating Cash Flow

-$58.32M

Capital Expenditure

-$781.00K

Free Cash Flow

-$59.10M

Cash & ST Invst.

$109.96M

Total Debt

$21.77M

Orchestra BioMed Performance Analysis

Orchestra BioMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,533,000N/A
20232023-12-31USD 2,760,000-21.9%
20242024-12-31USD 2,638,000-4.4%
20252025-12-31USD 33,482,0001169.2%
Orchestra BioMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.0%
Q42025-12-313490.8%
Q12026-03-31-99.6%
Q22026-06-30-20.0%
Orchestra BioMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2412020.0%
20232023-12-31USD -1.48-34.1%
20242024-12-31USD -1.6612.1%
20252025-12-31USD -1.11-33.1%
Orchestra BioMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.0%
Q42025-12-31130.0%
Q12026-03-31-375.0%
Q22026-06-30-15.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$88.00K

-89.5%

Gross Profit

$63.00K

-92.0%

Gross Margin

71.59%

N/A

Market Cap

$322.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.75M

N/A

Employees

86

N/A

Net Income

-$23.76M

-22.7%

EBITDA

-$23.66M

-22.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$109.96M

+224.1%

Total Debt

$21.77M

+33.1%

Accounts Receivable

$51.00K

-38.6%

Inventory

$250.00K

+35.1%

Long Term Debt

$20.96M

+33.4%

Short Term Debt

$808.00K

+25.9%

Return on Assets

-51.02%

N/A

Return on Invested Capital

-56.73%

N/A

Free Cash Flow

-$19.59M

-25.9%

Operating Cash Flow

-$19.33M

-24.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IVVDInvivyd, Inc.
$1.00+4.81%
PRLDPrelude Therapeutics Incorporated
$6.63+2.00%
ENTAEnanta Pharmaceuticals, Inc.
$13.47+2.59%
IVAInventiva S.A.
$4.68+0.65%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About OBIO

What is the current price of Orchestra BioMed?

Orchestra BioMed is trading at $5.36 per share.

What is the 52-week range for Orchestra BioMed?

Over the past 52 weeks, Orchestra BioMed has traded between $2.20 and $5.78.

How much debt does Orchestra BioMed have?

As of the most recent reporting period, Orchestra BioMed reported total debt of $70.76M.

How much cash does Orchestra BioMed have on hand?

Orchestra BioMed reported $20.47M in cash and cash equivalents in its most recent financial results.

What is Orchestra BioMed’s dividend yield?

Orchestra BioMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services